Pak firing kills 2 Army jawans, one woman; triggers migration

January 3, 2015

Srinagar/Jammu, Jan 3: Two army jawans and a woman were killed while 11 people were injured as Pakistani troops targeted villages and security posts at various places in Jammu and Kashmir since last night which triggered migration of hundreds of people from some border areas.pak firing

While the firing and shelling continued, Home Minister Rajnath Singh regretted that Pakistan is repeatedly targeting border areas of India despite being offered a hand of friendship.

Pakistani troops violated the ceasefire along the LoC near Kanhaiyah Post last night by firing rocket propelled grenades into Tanghdar area, police officials said while citing the FIR lodged by the army.

They said the Pakistani action caused death of two army jawans and injury to another. A BSF jawan, who was posted on duty in a nearby post of the force, was also injured in the incident, the officials said.

Along the International Border, Pakistani troops targeted villages and 13 border outposts with heavy mortar shelling in Kathua and Samba districts of Jammu and Kashmir, leading to death of a woman and injuries to eight others.

Shelling of villages triggered panic and migration from border villages and over 1400 people have been evacuated from hamlets in Samba and Kathua district, officials said.

"Pakistani troops resorted to unprovoked and heavy firing and mortar shelling on posts and civilian areas along IB in Samba and Kathua districts since 2130 hours last night," Inspector General of BSF Rakesh Sharma told PTI.

"BSF troops gave a befitting reply resulting in exchanges which stopped at 3 AM in the morning," the IG said.

Pakistan again started mortar shelling and firing targeting civilian areas since 7 AM, he said.

He said all BoPs in three battalion areas of Samba and Hiranagar sub-sectors in Kathua district were targeted.

A woman identified as Tori Devi of village Mangu Chack has been killed in the shelling and four civilians have been injured in the firing and shelling, Senior Superintendent of Police (SSP), Samba, Anil Magotra told reporters.

Four persons, including two women, were injured in Nauchak village in Kathua, Deputy Commissioner Kathua Shahid Iqbal said.

IG BSF has also issued an advisory to the border people for evacution.

Scores of houses have suffered damage and few animals have also perished in the firing, Magotra said.

The SSP said buses have been kept ready for evacuation and "we are waiting for the firing and shelling to stop so that people are shifted to safer areas in shelter camps".

People have taken shelter in bunkers and are not venturing out, he said.

The latest round of firing by Pakistan which started on New Year eve has left two persons dead, including a BSF jawan, and nine injured while five Pakistani Rangers have been killed in retaliatory firing by India.

Commenting on this, Rajnath Singh said in Delhi, "Pakistan should stop ceasefire violations."

He wondered why Pakistan was continuously indulging in ceasefire violations despite having suffered badly every time.

"While we are offering our hand of friendship to Pakistan, it is continuously indulging in ceasefire violations. We made a beginning by inviting Pakistan Prime Minister Nawaz Sharif at the swearing-in of Prime Minister Narendra Modi, who shook hands with him offering not just friendship but also hoping to unite hearts. Despite that, Pakistan is indulging in ceasefire violations repeatedly," he said.

He said India wants good ties with all our neighbouring countries, including Pakistan.

The renewed ceasefire violations come barely two months after the last major escalation that left 13 people dead and displaced 32,000 border residents in August and October.

Over 550 incidents of ceasefire violations by Pakistan occurred in 2014, the highest since the truce came into force in 2003, with the Indo-Pak border witnessing the worst such escalation during August to October which left 13 people, including 2 security personnel dead.

A total of 19 people, including 5 jawans, were killed and over 150 injured in such incidents last year.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
February 8,2020

New Delhi, Feb 8: A 26-year-old woman sub-inspector (SI) of the Delhi Police was shot dead near Rohini East Metro station on Friday night, officials said.

The SI, Preeti Ahlawat, was posted in Patparganj Industrial Area Police Station, police said.

A call about the incident was received around 9.30 pm, they said, adding she received gunshot wounds on her head.

"We have identified the suspects and CCTV footage of the area has been collected," said SD Mishra, Additional Commissioner of Police (Rohini).

Three empty cartridges were found from the spot, the officer said, adding a case has been registered and a probe is on.

Personal enmity is suspected to be the reason behind the killing, the officer said.

Ahlawat joined the Delhi Police in 2018.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
February 4,2020

New Delhi, Feb 4: The investigation into the incident of violence at Jamia Millia Islamia during an anti-citizenship law protest was at a crucial stage, the Centre told the Delhi High Court on Tuesday.

The submission before a bench of Chief Justice D N Patel and Justice C Hari Shankar was made by Solicitor General Tushar Mehta while seeking more time to file a report regarding the probe.

Taking note of the submission, the bench granted the Centre time till April 29 to file a reply.

During the hearing, senior advocate Colin Gonsalves, appearing for some students of Jamia, said 93 students and teachers filed complaints about alleged attacks on them by police but no FIR has been filed against the agency till date.

The other lawyers for the petitioners alleged that the government has not complied with the court order to file a response within four weeks of the last date of hearing on December 19.

The bench, however, declined to pass any interim order and granted time till April 29 to the government to file a reply.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 3,2020

The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical trials of the Oxford University developed Covid-19 vaccine candidate in the country.

Government officials said that the approval for conducting phase 2 and 3 clinical trials by the SII was granted by DCGI Dr V G Somani late Sunday night after a thorough evaluation based on the recommendations of the Subject Expert Committee (SEC) on Covid-19.

"The firm has to submit safety data, evaluated by the Data Safety Monitoring Board (DSMB), to the CDSCO before proceeding to phase 3 clinical trials," a senior official said.

"As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals," the official said.

As a rapid regulatory response, the expert panel at the Central Drugs Standard Control Organisation (CDSCO) on Friday, after a detailed deliberation and considering the data generated on the vaccine candidate in phase 1 and 2 of the Oxford University trial, had recommended granting permission for phase 2 and 3 clinical trials of the potential vaccine, 'Covishield', on healthy adults in India,  the officials said.

Currently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is going on in the United Kingdom, phase 3 clinical trial in Brazil and phase 1 and 2 clinical trials in South Africa.

The officials said that the SII had submitted a revised proposal on Wednesday after the SEC on July 28, following deliberation over its application, had asked it to revise its protocol for the phase 2 and 3 clinical trials besides seeking some additional information.

The panel had also recommended that the clinical trial sites which have been proposed for the study be distributed across India.

According to the revised proposal by the SII, 1,600 people aged above 18 years will participate in the trials across 17 selected sites, including AIIMS-Delhi, B J Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS-Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore.

"According to the application, it would conduct an observer-blind, randomised controlled study to determine the safety and immunogenicity of 'Covishield' on healthy Indian adults," the official said.

The SII, which has partnered with AstraZeneca, for manufacturing the Oxford vaccine candidate for Covid-19 had submitted its first application to the DCGI on July 25 seeking permission for conducting the phase 2 and 3 trials of the potential vaccine. 

Initial results of the first two-phases of trials of the vaccine conducted in five trial sites in the UK showed that it has an acceptable safety profile and homologous boosting increased antibody response, sources had said.

To introduce the vaccine, SII, the world's largest vaccine maker by number of doses produced and sold, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute (Oxford University) in collaboration with British-Swedish pharma company AstraZeneca. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.